Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) EBITDA Margin (2016 - 2026)

Ekso Bionics Holdings has reported EBITDA Margin over the past 13 years, most recently at 148.6% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 10011.0% to 148.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 104.26%, a 4552.0% decrease, with the full-year FY2025 number at 104.26%, down 4552.0% from a year prior.
  • EBITDA Margin reached 148.6% in Q4 2025 per EKSO's latest filing, down from 34.02% in the prior quarter.
  • The five-year high for EBITDA Margin was 34.02% in Q3 2025, with the low at 185.51% in Q2 2025.
  • The 5-year median for EBITDA Margin is 80.88% (2023), against an average of 93.72%.
  • Peak YoY movement for EBITDA Margin: surged 46504bps in 2021, then crashed -13856bps in 2025.
  • Tracing EKSO's EBITDA Margin over 5 years: stood at 64.62% in 2021, then tumbled by -79bps to 115.49% in 2022, then skyrocketed by 32bps to 78.21% in 2023, then soared by 38bps to 48.49% in 2024, then crashed by -206bps to 148.6% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 148.6%, 34.02%, and 185.51% for Q4 2025, Q3 2025, and Q2 2025 respectively.